Simplify Logo
Otsuka Pharmaceutical

Otsuka Pharmaceutical

Global pharma maker of Abilify

Medical Safety Physician - Multiple Teams

Full-Time
$250k - $388.1k/yr

+ Incentive opportunity

Expert
MD
Remote in USA
Remote

Remote within the United States, with approximately 20% travel and occasional after-hours meetings with Japan.

About the job

Requirements
  • Ability to lead and operate in a highly ambiguous and evolving regulatory and scientific space.
  • Strong decision-making ability within a rapidly evolving external landscape.
  • Exceptional communication and cross-functional collaboration.
  • Ability to influence without authority.
  • A strong medical background evidenced by clinical training.
  • A proven track record of innovation in Medical Safety strategy, implementation, and execution.
  • Proven strategic resource management experience, including applying strategic planning, deployment, and utilization of resources and technology to fulfill the organization or department’s mission.
  • Proven business and market knowledge, including understanding stakeholder needs regarding business environments and developing strategies to maximize organizational value.
  • Solid knowledge of Food and Drug Administration and global pharmacovigilance regulations.
  • Knowledge of clinical trials, good clinical practices, and International Council for Harmonisation guidelines.
  • Experience preparing and reviewing safety content for global regulatory filings, including Investigational New Drug applications, New Drug Applications, and Marketing Authorisation Applications.
  • Experience working in a global setting.
  • Excellent technical skills, including the ability to comprehend and integrate scientific data from a variety of sources.
  • Knowledge of how and when to apply organizational policy or procedures to a variety of situations.
  • Ability to thrive in a fast-paced team environment while handling multiple simultaneous high-priority tasks.
  • Ability to adapt to a dynamic work environment and drive safety initiatives.
  • An MD degree is required.
  • At least 10 years of experience as a safety or pharmacovigilance professional in the pharmaceutical industry.
  • Ability to act as an in-house authority and leader in Global Pharmacovigilance and be fully accountable for the safety of assigned products.
  • High level of medical competence, with an ability to balance this with industry standards to achieve business goals.
  • Thorough knowledge of the pharmaceutical and biopharmaceutical industry, especially clinical research, global regulatory requirements, and practices governing expedited and periodic safety reporting, signal generation, safety evaluation, and risk management activities.
  • Ability to work across therapeutic areas and functions.
  • Experience interacting with global regulatory authorities.
Responsibilities
  • Lead and support safety teams in all aspects of pharmacovigilance and risk management activities for assigned marketed and investigational products.
  • Provide proactive strategic and operational safety leadership for Otsuka’s late-stage psychedelic development portfolio.
  • Serve as the medical safety lead for investigational psychedelic compounds, ensuring proactive identification, assessment, communication, and mitigation of safety risks.
  • Establish a robust safety strategy that supports accelerated development while maintaining patient safety and scientific integrity.
  • Partner with Medical Safety Therapeutic Area Lead, Head of Medical Safety, Head of Global Pharmacovigilance, Global Clinical Development, Clinical Management, Global Regulatory Affairs, Biometrics, and Translational Medicine to identify, evaluate, and communicate safety issues relevant to the psychedelic portfolio.
  • Serve as the medical safety expert for assigned products from late-stage development through commercialization.
  • Maintain accurate and complete knowledge of assigned investigational and marketed products monitored by Otsuka, co-marketers, cosponsors, and affiliates.
  • Develop and lead the global safety strategy for the late-stage psychedelic development portfolio.
  • Develop a safety monitoring approach for the psychedelic class, including acute altered states of consciousness, perceptual disturbances, emotional dysregulation, and prolonged psychological effects.
  • Partner with Global Clinical Development, Clinical Management, and Global Regulatory Affairs to define therapist or guide escalation procedures and emergency intervention frameworks.
  • Develop integrated benefit-risk frameworks tailored to psychedelic-assisted therapies and novel neuropsychiatric mechanisms.
  • Serve as the safety representative on asset strategy and governance teams, including Product Development Committees and Research and Development Teams.
  • Contribute to the therapeutic product profile and overall development strategy.
  • Establish standards for psychological safety monitoring before, during, and after dosing sessions.
  • Chair product-level safety governance cross-functional meetings.
  • Provide strategic regulatory safety leadership and author safety content for Phase 2 and Phase 3 protocols and global regulatory submissions, including Investigational New Drug applications, New Drug Applications, Marketing Authorisation Applications, and other health authority filings.
  • Represent Global Safety in regulatory interactions by presenting and defending safety findings, emerging safety signals, and benefit-risk evaluations and providing scientific and clinical interpretation for regulatory decision-making.
  • Author safety surveillance plans and review case report forms, investigator brochures, clinical study reports, package inserts, New Drug Application documents, Product License Application documents, and patient narratives.
  • Perform medical analysis and assess patient safety impacts for product quality and other quality-related events.
  • Keep abreast of industry standards and initiatives regarding signal detection, risk management, and risk communication.
  • Represent Global Pharmacovigilance in Labeling Committee and Executive Committee discussions regarding new information affecting the product profile.
  • Manage the continuous analysis of adverse events to identify signals and trends for assigned products.
  • Review and approve clinical trial medical coding.
  • Participate in the creation and revision of standard operating procedures.
  • Provide strategic input on safety issues during development portfolio reviews and governance meetings.
  • Prepare and review safety summaries for medical information write-ups, including analysis of similar events in alert reports.
  • Provide medical analysis and decision-making for the development and maintenance of the Company Core Data Sheet, risk management plans, Risk Evaluation and Mitigation Strategies, and individual case safety reports.
  • Keep management informed of critical safety issues on monitored products.
  • Serve as mentor and resource for Global Pharmacovigilance associates, scientists, and safety physicians.
  • Provide training to Global Pharmacovigilance team members and other Otsuka staff on epidemiological and regulatory aspects of programs.
  • Participate in inspection and audit readiness activities as a medical safety subject matter expert.
  • Use technical and medical knowledge to assist Global Pharmacovigilance team members in assessing adverse event reports.
  • Maintain knowledge of current developments by attending seminars, professional association meetings, and maintaining industry and professional networks.
  • Travel approximately 20% as required.
  • Participate in occasional after-hours meetings with Japan.
Desired Qualifications
  • Experience with psychedelic-assisted therapy clinical trials.
  • Knowledge of controlled substance regulations and Drug Enforcement Administration requirements.
  • Experience with suicidality monitoring tools such as the Columbia-Suicide Severity Rating Scale and abuse liability monitoring.

About the company

Otsuka Pharmaceutical

Otsuka Pharmaceutical

View

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • VOYXACT’s July 2026 VISIONARY data showed two-year eGFR stabilization and kidney-failure risk reduction.
  • SIMTRIYO cleared FDA review on July 24, 2026, opening a large ADHD market.
  • Japan covered Paradise renal denervation on March 1, 2026, accelerating cardiovascular device revenue.

What critics are saying

  • VOYXACT remains accelerated-approval dependent until the FDA accepts its confirmatory 2026 traditional filing.
  • SIMTRIYO cannot launch until DEA scheduling, delaying cash collection and ceding early prescriptions.
  • Otsuka still depends on a few launches; VOYXACT failure or Simtriyo slowdown would crush growth.

What makes Otsuka Pharmaceutical unique

  • SIMTRIYO became Otsuka’s first U.S. ADHD launch, expanding its CNS franchise on July 24, 2026.
  • VOYXACT gave Otsuka first U.S. APRIL inhibition and traditional-approval runway in IgAN.
  • Astex’s fragment-based platform secured Genentech’s breast-cancer pact on July 6, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.

Associated Press
Mar 25th, 2026
Otsuka's Voyxact shows 82.5% hematuria improvement in IgA nephropathy trial at 48 weeks

Otsuka presented new Phase 3 VISIONARY trial data for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy patients at the 2026 ISN World Congress of Nephrology. The analyses showed 82.5% of patients receiving sibeprenlimab achieved negative microscopic hematuria at week 48, compared with 52.6% on placebo. Median time to achieve hematuria negativity was nine weeks versus 24 weeks for placebo. VOYXACT, approved under accelerated approval in the US, is a monoclonal antibody that inhibits APRIL, a key driver in IgAN pathogenesis. Previously reported data showed the drug met its primary endpoint with a 51.2% placebo-adjusted reduction in proteinuria at nine months. The trial continues evaluating sibeprenlimab's effect on preserving kidney function over 24 months.